|
KMID : 0985520170220030127
|
|
Korean Journal of Pancreas and Biliary Tract
2017 Volume.22 No. 3 p.127 ~ p.133
|
|
|
Effect of Capecitabine plus Oxaliplatin for Advanced Adenocarcinoma of Ampulla of Vater
|
|
Lee Jung-Hwan
Kim Kyung-Hee
Woo Sang-Myung
Park Sang-Jae
Han Sung-Sik
Hong Eun-Kyung
Ko Young-Hwan
Lee Ju-Hee
Lee Woo-Jin
|
|
|
Abstract
|
|
|
Background/Aim: Adenocarcinoma arising from the ampulla of Vater is a rare disease and has limited data regarding outcome of palliative chemotherapy. We investigated the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with advanced ampullary adenocarcinoma.
Methods: From October 2006 to January 2014, we retrospectively analyzed 28 patients with advanced ampullary adenocarcinoma treated by XELOX regimen at single institution. All the patients had histologically confirmed stage IV or recurrent ampullary adenocarcinoma. XELOX was administered in outpatient clinic every 3 weeks according to the following protocol: oral administration of capecitabine 750 mg/m2 twice a day on days 1-14 and intravenous injection of oxaliplatin 130 mg/m2 on day 1.
Results: With follow-up of median 24.6 months (range 4.0-78.0 months), median progression-free survival (PFS) was 4.8 months (range 0.7-26.1 months), and median overall survival (OS) was 11.9 months (range 2.0-36.0 months). One patient (4%) achieved complete response and 5 patients (18%) showed partial response. There were no significant differences for PFS and OS according to response by chemotherapy. The most common grade 3 adverse events in patients were nausea and vomiting (10.7%). There was no treatment-related mortality.
Conclusions: XELOX regimen is well tolerated and show moderate activity against advanced ampullary adenocarcinoma.
|
|
|
KEYWORD
|
|
|
Adenocarcinoma, Ampulla of Vater, Capecitabine, Oxaliplatin, Antineoplastic agents
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|